Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer

Sponsor
National Guard Health Affairs
Study ID
NCT01320501
Phase
PHASE4
Status
Suspended

Conditions

  • Non-small Cell Lung Cancer Metastatic

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Erlotinib — DRUG
    All patients will receive: TarcevaTM 150mg/day PO.

Study Details

An open-label, prospective, single-arm, multi-center phase IV clinical trial of TarcevaTM as single agent

Key Dates

First listed
Mar 22, 2011
Start date
Oct 31, 2009
Status verified
May 2016
Primary completion
Aug 31, 2016
Completion
Aug 31, 2016

Study Design

Enrollment
100 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Erlotinib
    150 mg PO daily

Primary Outcome Measure

To evaluate the pattern of use of TarcevaTM in Middle Eastern patients with advanced NSCLC [ Time Frame: 3 years ]

Related Studies